

Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER : UK API 15020 Insp GMP 15020/5982-0009

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1),(2)

Part 1

Issued following an inspection in accordance with :

Regulation 331A of The Human Medicines Regulations 2012 (SI 2012/1916)

The competent authority of United Kingdom confirms the following :

The Manufacturer : HIGH FORCE RESEARCH LIMITED

Site address : HIGH FORCE RESEARCH LIMITED, BOWBURN NORTH INDUSTRIAL ESTATE, BOWBURN, DURHAM, DH6 5PF, UNITED KINGDOM

Is an active substance manufacturer that has been inspected in accordance with Regulation 327 of The Human Medicines Regulations 2012 (SI 2012/1916).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 19/03/2025 , it is considered that it complies with

- The principles of GMP for active substances referred to in Regulation B17 and C17 of the Human Medicines Regulations 2012 (SI 2012/1916)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

-
- (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
 - (2) These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products

Manufacture of active substance. Names of substances subject to inspection :

- [2000019379] EP0042 FUMARATE
- [1000018046] ACTIVE SUBSTANCES FOR CLINICAL TRIALS
- [3000024079] EDV2209

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

EP0042 FUMARATE

- 3.1 Manufacture of Active Substance by Chemical Synthesis
- 3.1.1 Manufacture Of Active Substance Intermediates
- 3.1.2 Manufacture Of Crude Active Substance
- 3.1.3 Salt Formation/Purification steps (eg. Crystallisation)
The multistep synthesis of EP0042 included recrystallisation of the free base and formation of the fumarate salt
- 3.5 General Finishing Steps
- 3.5.2 Primary Packaging
- 3.5.3 Secondary Packaging
- 3.6 Quality Control Testing
- 3.6.1 Physical / Chemical testing

ACTIVE SUBSTANCES FOR CLINICAL TRIALS

- 3.1 Manufacture of Active Substance by Chemical Synthesis
- 3.1.1 Manufacture Of Active Substance Intermediates
- 3.1.2 Manufacture Of Crude Active Substance
- 3.1.3 Salt Formation/Purification steps (eg. Crystallisation)
Purification by recrystallisation and salt formation
- 3.5 General Finishing Steps
- 3.5.2 Primary Packaging
- 3.5.3 Secondary Packaging
- 3.6 Quality Control Testing
- 3.6.1 Physical / Chemical testing

EDV2209

- 3.1 Manufacture of Active Substance by Chemical Synthesis
- 3.1.1 Manufacture Of Active Substance Intermediates
- 3.1.2 Manufacture Of Crude Active Substance
- 3.1.3 Salt Formation/Purification steps (eg. Crystallisation)
Purification by recrystallisation
- 3.6 Quality Control Testing
- 3.6.1 Physical / Chemical testing

Restrictions or Remarks

This certificate covers the cytotoxic and non cytotoxic clean rooms and support areas including QC, solvent and equipment storage which are used for the manufacture of API for clinical trials.

This certificate is issued based on a desk-based assessment of GMP compliance information provided by the manufacturer. This certificate should be used in combination with the relevant authorisation/registration. A risk-based site inspection programme remains in force.

Any restrictions related to the scope of this certificate:

Building	Room	Line/equipment	QC Testing	Products
----------	------	----------------	------------	----------

This certificate is valid for the manufacture of APIs for use in clinical trials only.				
--	--	--	--	--

19/03/2025	Name and signature of the authorised person of the Competent Authority of United Kingdom
	Confidential
	Medicines and Healthcare products Regulatory Agency
	Tel : Confidential